MedTrace Logo

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

NCT06089486 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2026-05-06

No results posted yet for this study

Summary

Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.

Conditions

  • Cardiac Allograft Vasculopathy

Interventions

DIAGNOSTIC_TEST

ICA

Patients will undergo annual CAV surveillance with ICA

DIAGNOSTIC_TEST

PET

Patients will undergo annual CAV surveillance with PET

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Sharon Chih · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2028-10-31
Completion
2029-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089486 on ClinicalTrials.gov